March 19, 2020
1 min read

Visual acuity, injection frequency decrease over time in real-world AMD study

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

In a retrospective study, patients with neovascular age-related macular degeneration treated with anti-VEGF injections experienced decreased visual acuity from baseline and decreased number of injections at 4 years’ follow-up, according to a study.

“In this large real-world study looking at 98,821 eyes from 79,885 patients, with up to 4-year follow-up, both [visual acuity] and injection frequency declined over time. The study highlights the treatment burden experienced by the patients with [neovascular] AMD and need for durable treatment options to have better vision acuity outcomes in the real world,” study co-author Arshad M. Khanani, MD, MA, told Healio/OSN.

The retrospective, multicenter, noninterventional real-world evidence study included 98,821 eyes that received intravitreal anti-VEGF therapy for neovascular AMD from 2012 to 2015. Researchers evaluated the change in visual acuity from baseline, treatment frequencies, annual anti-VEGF injections, bilateral treatment frequencies, annual total clinic visits and non-injection clinic visits as the main outcome measures in the study.

Baseline visual acuities in 2012, 2013 and 2014 were similar, with 53.6 ETDRS letters, 53.2 ETDRS letters and 53.1 ETDRS letters, respectively. However, the baseline visual acuity in 2015 was lower, with an average of 50.7 ETDRS letters. The overall visual acuity for the entire population from 2012 to 2015 was 52.6 ETDRS letters.

The mean number of injections decreased from 7.5 at year 1 to 6.4 injections at year 4. By year 4, 36.7% of eyes had an 8-week or less dosing interval and 21.2% had a 12-week or greater dosing interval. Eyes treated every 8 weeks increased 40% from year 1 to year 4. – by Robert Linnehan

Disclosure: Khanani reports he is a consultant for Adverum, Aerpio, Alcon, Alimera, Allegro, Allergan, Genentech, Novartis, Opthea, PolyPhotonix, Recens Medical, Regenxbio and Oxurion; receives financial support from Aerpio, Adverum, Alcon, Allergan, Clearside Biomedical, DigiSight, Genentech, Kodiak, Novartis, Ophthotech, Opthea and Oxurion; and is a lecturer with Allergan, Genentech and Novartis.